RecruitingPhase 2NCT06939855
QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma
Studying Bone sarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sun Yat-sen University
- Intervention
- QL1706 (bispecific antibody targeting PD-1 and CLTA-4)(drug)
- Enrollment
- 45 target
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2025 – 2028
Study locations (1)
- Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06939855 on ClinicalTrials.govOther trials for Bone sarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07479732Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic OsteosarcomaPeking University People's Hospital
- RECRUITINGPHASE1NCT07222735Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory SarcomasSt. Jude Children's Research Hospital
- RECRUITINGPHASE2NCT07359053MAGNATE-S: Paclitaxel Polymer Micelles Combo in Advanced SarcomaShanghai 6th People's Hospital
- RECRUITINGNCT07215611Financial Toxicity in Patients With Resected Soft Tissue and Bone SarcomasM.D. Anderson Cancer Center
- RECRUITINGNCT06958107LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma PatientsWake Forest University Health Sciences
- RECRUITINGPHASE1, PHASE2NCT07066982Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced SarcomasEssen Biotech
- RECRUITINGNANCT06796543Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone SarcomaSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- RECRUITINGPHASE1, PHASE2NCT06709495Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory SarcomasDavid S Shulman, MD